Association of the Plasma Long Non-coding RNA With Parkinson's Disease.

To investigate the expression level of the maternally expressed gene-3 () of the free long non-coding RNA (lncRNAs) in the plasma of Parkinson's disease (PD) patients and its relationship with the disease. Thirty PD patients (PD group) who treated at Xuanwu Hospital of Capital University of Medical Sciences between January 2017 and December 2019 were selected as the research objects and 30 healthy subjects were enrolled in the study during the same period as the control group. Cognitive function was assessed according to the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to evaluate cognitive function, Non-Motor Symptoms Scale (NMSS) was used to evaluate severity of non-motor symptoms. The relative expression of lncRNAs in plasma was measured by PCR, and the levels of neuron-specific enolase (NSE), nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in plasma were measured by ELISA, and the relationship with these all indexes was analyzed. The NMSS score of PD group was significantly higher than that of the control group, while the MMSE and MoCA scores were significantly lower than that of the control group ( < 0.05); The relative expression of lncRNAs , NGF and BDNF levels of PD group were significantly lower than that of the control group, and NSE level was significantly higher than that of the control group ( < 0.05); The H&Y stage and NMSS score in PD group were negatively correlated with the relative expression of lncRNAs , the levels of NGF and BDNF ( < 0.05), and positively correlated with NSE ( < 0.05); The MMSE and MoCA scores in PD group were positively correlated with the relative expression of lncRNAs , NGF, BDNF levels ( < 0.05), and negatively correlated with NSE ( < 0.05); The relative expression of lncRNAs in PD group was positively correlated with NGF, BDNF levels ( < 0.05), and negatively correlated with NSE ( < 0.05). The expression of lncRNAs in the plasma of PD patients was downregulated compared to that of healthy control subjects, and its expression level was closely related to the aggravation of non-motor symptoms, cognitive decline, and PD stage. These associations may reflect the synergism of the increase of NSE and decrease of NGF and BDNF levels, highlighting plasma lncRNA as a new candidate biomarker of PD.